Sponsors (4)
The bill strengthens U.S. medical supply resilience and manufacturing and speeds cross‑border cooperation, but it does so at the cost of higher potential procurement and taxpayer expenses, regulatory and privacy risks, and greater procedural and diplomatic complexity.
Hospitals, health systems, and patients (especially those with chronic conditions) would face fewer shortages and more reliable access to medicines, devices, and supplies during crises because the bill promotes diversified, trusted supply chains and targeted protections for medical goods.
U.S. medical manufacturers, small suppliers, and local economies would gain expanded domestic production and R&D opportunities because the bill incentivizes investment, manufacturing capacity expansion, and cross‑border R&D cooperation.
Patients, hospitals, and health researchers would benefit from faster market entry and cross‑border movement of critical medical goods and data when appropriate because the bill promotes regulatory harmonization, transparency, and expedited pathways for life‑science products.
Hospitals, taxpayers, and consumers could face higher costs because diversifying or reshoring supply chains, providing subsidies/incentives, and reducing tariff revenue can increase production and procurement expenses.
Domestic medical manufacturers and some U.S. suppliers could face increased foreign competition and market share loss if the bill lowers trade barriers or duties, threatening U.S. production jobs.
Patients and hospitals could face safety risks if regulatory harmonization or expedited approvals weaken domestic oversight or lower safety standards during alignment or fast‑track reviews.
Based on analysis of 7 sections of legislative text.
Allows the President to make "trusted trade partner" agreements to cut or remove trade barriers on medical goods, with required consultation, congressional review, monitoring, and enforcement.
Introduced March 12, 2025 by Thomas Roland Tillis · Last progress March 12, 2025
Authorizes the President to negotiate and enter into "trusted trade partner" agreements with foreign countries to reduce or eliminate tariffs, quotas, and other trade restrictions on medical goods and their inputs in order to strengthen U.S. medical supply chain resilience for national security and public health. The law requires agency consultations, periodic reports to Congress, a formal congressional review-and-disapproval window before tariff changes take effect, ongoing monitoring by the USTR, and fast corrective actions if a partner fails to meet commitments.